vitality.jeuveauuseeme.com
Open in
urlscan Pro
3.101.12.193
Public Scan
URL:
https://vitality.jeuveauuseeme.com/
Submission: On April 23 via api from US — Scanned from DE
Submission: On April 23 via api from US — Scanned from DE
Form analysis 6 forms found in the DOM
POST
<form id="contact-form" method="post" class="form-inline mt-3 py-0 pb-md-5 schedule-form needs-validation" novalidate="">
<input type="hidden" name="emailto" value="info@vitalityhealthwell.com">
<input type="hidden" name="bcc" value="etvleads@evolus.com, nicolas.espana@evolus.com">
<input type="hidden" name="id" value="573">
<input type="hidden" name="t" value="XsF3RjL67ZdQGa5qBM7t2ytGHUVMQO">
<input name="evolusforminfo" type="text" id="evolusforminfo" class="myblank">
<div class="row no-gutters">
<div class="col-md-6 px-0 pr-md-1">
<div class="form-group"> <input type="text" name="first_name" class="form-control" id="inputfirstinline" placeholder=" First Name" required=""> </div>
</div>
<div class="col-md-6 px-0 pr-md-1">
<div class="form-group"> <input type="text" name="last_name" class="form-control" id="inputlastinline" placeholder=" Last Name " required=""> </div>
</div>
<div class="col-md-6 px-0 pr-md-1">
<div class="form-group"> <input type="email" name="email" class="form-control" id="inputmailinline" placeholder=" E-mail" required=""> </div>
</div>
<div class="col-md-6 px-0 pr-md-1">
<div class="form-group"> <input type="phone" name="phone" class="form-control" id="inputphoneinline" placeholder=" Phone " required=""> </div>
</div>
</div>
<div id="recaptcha" class="g-recaptcha" data-sitekey="6Ldaza4oAAAAACWxYmJc2goFIaFcBou0ib2MOQsf" data-callback="onSubmit" data-error-callback="onGerror" data-size="invisible">
<div class="grecaptcha-badge" data-style="bottomright"
style="width: 256px; height: 60px; display: block; transition: right 0.3s ease 0s; position: fixed; bottom: 14px; right: -186px; box-shadow: gray 0px 0px 5px; border-radius: 2px; overflow: hidden;">
<div class="grecaptcha-logo"><iframe title="reCAPTCHA" width="256" height="60" role="presentation" name="a-p2dhhvdrvp4s" frameborder="0" scrolling="no"
sandbox="allow-forms allow-popups allow-same-origin allow-scripts allow-top-navigation allow-modals allow-popups-to-escape-sandbox allow-storage-access-by-user-activation"
src="https://www.google.com/recaptcha/api2/anchor?ar=1&k=6Ldaza4oAAAAACWxYmJc2goFIaFcBou0ib2MOQsf&co=aHR0cHM6Ly92aXRhbGl0eS5qZXV2ZWF1dXNlZW1lLmNvbTo0NDM.&hl=de&v=QoukH5jSO3sKFzVEA7Vc8VgC&size=invisible&cb=lvp2e7lombkv"></iframe>
</div>
<div class="grecaptcha-error"></div><textarea id="g-recaptcha-response" name="g-recaptcha-response" class="g-recaptcha-response"
style="width: 250px; height: 40px; border: 1px solid rgb(193, 193, 193); margin: 10px 25px; padding: 0px; resize: none; display: none;"></textarea>
</div><iframe style="display: none;"></iframe>
</div>
<button type="submit" name="submit" class="btn btn-primary w-100 mb-2 schedule-submit-button rounded-0 form text-uppercase">Submit </button>
<span class="disclaimer">By submitting this form, I consent to Evolus, Inc., under its express authorized partnership with Vitality Health and Wellness, to use my information for contact regarding consultations or services. I understand that
Evolus, Inc. manages this process on behalf of Vitality Health and Wellness. This may include automated messages. As outlined in the <a href="https://www.evolus.com/privacy-policy/" target="_blank" class="footer-nav-link">Privacy Policy</a> I am
aware I can opt out of these communications at any time.</span>
</form>Name: wf-form-Before-After-Slider — GET
<form id="wf-form-Before-After-Slider" name="wf-form-Before-After-Slider" data-name="Before After Slider" method="get" data-wf-page-id="64b85a416741fe7c912424a9" data-wf-element-id="8251b795-560c-bf7a-9719-5444a5e025ca"
aria-label="Before After Slider">
<div ba-slider-id="Soo Youn" class="html-embed-2 w-embed">
<style>
input[type="range"] {
-webkit-appearance: none;
/* Hides the slider so that custom slider can be made */
width: 100%;
/* Specific width is required for Firefox. */
background: transparent;
/* Otherwise white in Chrome */
}
input[type="range"]:focus {
outline: 1px solid rgba(0, 0, 0, 0);
/* Removes the blue border. You should probably do some kind of focus styling for accessibility reasons though. */
}
input[type="range"]::-ms-track {
width: 100%;
cursor: pointer;
/* Hides the slider so custom styles can be added */
background: transparent;
border-color: transparent;
color: transparent;
}
/* Special styling for WebKit/Blink */
input[type="range"]::-webkit-slider-thumb {
-webkit-appearance: none;
background: no-repeat center/100% url("https://uploads-ssl.webflow.com/646e7e37a48980ea23027e0b/64a9bb1753a8cd97b6130dd6_slider-thumb.png");
width: 64px;
height: 38.12px;
cursor: pointer;
margin-top: -14px;
/* You need to specify a margin in Chrome, but in Firefox and IE it is automatic */
margin-left: -1px;
outline: none;
border: none;
box-shadow: none;
}
/* All the same stuff for Firefox */
input[type="range"]::-moz-range-thumb {
background: no-repeat center/100% url("https://uploads-ssl.webflow.com/646e7e37a48980ea23027e0b/64a9bb1753a8cd97b6130dd6_slider-thumb.png");
width: 64px;
height: 38.12px;
cursor: pointer;
outline: none;
border: none;
box-shadow: none;
margin-left: -1px;
}
</style>
<div>
<input id="ba-slider" class="ba-slider" type="range" min="0" max="100" step="1" value="50">
</div>
</div>
</form>Name: wf-form-Before-After-Slider — GET
<form id="wf-form-Before-After-Slider" name="wf-form-Before-After-Slider" data-name="Before After Slider" method="get" data-wf-page-id="64b85a416741fe7c912424a9" data-wf-element-id="8251b795-560c-bf7a-9719-5444a5e025ca"
aria-label="Before After Slider" data-gtm-form-interact-id="0">
<div ba-slider-id="David" class="html-embed-2 w-embed">
<style>
input[type="range"] {
-webkit-appearance: none;
/* Hides the slider so that custom slider can be made */
width: 100%;
/* Specific width is required for Firefox. */
background: transparent;
/* Otherwise white in Chrome */
}
input[type="range"]:focus {
outline: 1px solid rgba(0, 0, 0, 0);
/* Removes the blue border. You should probably do some kind of focus styling for accessibility reasons though. */
}
input[type="range"]::-ms-track {
width: 100%;
cursor: pointer;
/* Hides the slider so custom styles can be added */
background: transparent;
border-color: transparent;
color: transparent;
}
/* Special styling for WebKit/Blink */
input[type="range"]::-webkit-slider-thumb {
-webkit-appearance: none;
background: no-repeat center/100% url("https://uploads-ssl.webflow.com/646e7e37a48980ea23027e0b/64a9bb1753a8cd97b6130dd6_slider-thumb.png");
width: 64px;
height: 38.12px;
cursor: pointer;
margin-top: -14px;
/* You need to specify a margin in Chrome, but in Firefox and IE it is automatic */
margin-left: -1px;
outline: none;
border: none;
box-shadow: none;
}
/* All the same stuff for Firefox */
input[type="range"]::-moz-range-thumb {
background: no-repeat center/100% url("https://uploads-ssl.webflow.com/646e7e37a48980ea23027e0b/64a9bb1753a8cd97b6130dd6_slider-thumb.png");
width: 64px;
height: 38.12px;
cursor: pointer;
outline: none;
border: none;
box-shadow: none;
margin-left: -1px;
}
</style>
<div>
<input id="ba-slider" class="ba-slider" type="range" min="0" max="100" step="1" value="50" data-gtm-form-interact-field-id="0">
</div>
</div>
</form>Name: wf-form-Before-After-Slider — GET
<form id="wf-form-Before-After-Slider" name="wf-form-Before-After-Slider" data-name="Before After Slider" method="get" data-wf-page-id="64b85a416741fe7c912424a9" data-wf-element-id="8251b795-560c-bf7a-9719-5444a5e025ca"
aria-label="Before After Slider">
<div ba-slider-id="Arielle" class="html-embed-2 w-embed">
<style>
input[type="range"] {
-webkit-appearance: none;
/* Hides the slider so that custom slider can be made */
width: 100%;
/* Specific width is required for Firefox. */
background: transparent;
/* Otherwise white in Chrome */
}
input[type="range"]:focus {
outline: 1px solid rgba(0, 0, 0, 0);
/* Removes the blue border. You should probably do some kind of focus styling for accessibility reasons though. */
}
input[type="range"]::-ms-track {
width: 100%;
cursor: pointer;
/* Hides the slider so custom styles can be added */
background: transparent;
border-color: transparent;
color: transparent;
}
/* Special styling for WebKit/Blink */
input[type="range"]::-webkit-slider-thumb {
-webkit-appearance: none;
background: no-repeat center/100% url("https://uploads-ssl.webflow.com/646e7e37a48980ea23027e0b/64a9bb1753a8cd97b6130dd6_slider-thumb.png");
width: 64px;
height: 38.12px;
cursor: pointer;
margin-top: -14px;
/* You need to specify a margin in Chrome, but in Firefox and IE it is automatic */
margin-left: -1px;
outline: none;
border: none;
box-shadow: none;
}
}
/* All the same stuff for Firefox */
input[type="range"]::-moz-range-thumb {
background: no-repeat center/100% url("https://uploads-ssl.webflow.com/646e7e37a48980ea23027e0b/64a9bb1753a8cd97b6130dd6_slider-thumb.png");
width: 64px;
height: 38.12px;
cursor: pointer;
outline: none;
border: none;
box-shadow: none;
margin-left: -1px;
}
</style>
<div>
<input id="ba-slider" class="ba-slider" type="range" min="0" max="100" step="1" value="50">
</div>
</div>
</form>Name: wf-form-Before-After-Slider — GET
<form id="wf-form-Before-After-Slider" name="wf-form-Before-After-Slider" data-name="Before After Slider" method="get" data-wf-page-id="64b85a416741fe7c912424a9" data-wf-element-id="8251b795-560c-bf7a-9719-5444a5e025ca"
aria-label="Before After Slider">
<div ba-slider-id="Sarah" class="html-embed-2 w-embed">
<style>
input[type="range"] {
-webkit-appearance: none;
/* Hides the slider so that custom slider can be made */
width: 100%;
/* Specific width is required for Firefox. */
background: transparent;
/* Otherwise white in Chrome */
}
input[type="range"]:focus {
outline: 1px solid rgba(0, 0, 0, 0);
/* Removes the blue border. You should probably do some kind of focus styling for accessibility reasons though. */
}
input[type="range"]::-ms-track {
width: 100%;
cursor: pointer;
/* Hides the slider so custom styles can be added */
background: transparent;
border-color: transparent;
color: transparent;
}
/* Special styling for WebKit/Blink */
input[type="range"]::-webkit-slider-thumb {
-webkit-appearance: none;
background: no-repeat center/100% url("https://uploads-ssl.webflow.com/646e7e37a48980ea23027e0b/64a9bb1753a8cd97b6130dd6_slider-thumb.png");
width: 64px;
height: 38.12px;
cursor: pointer;
margin-top: -14px;
/* You need to specify a margin in Chrome, but in Firefox and IE it is automatic */
margin-left: -1px;
outline: none;
border: none;
box-shadow: none;
}
/* All the same stuff for Firefox */
input[type="range"]::-moz-range-thumb {
background: no-repeat center/100% url("https://uploads-ssl.webflow.com/646e7e37a48980ea23027e0b/64a9bb1753a8cd97b6130dd6_slider-thumb.png");
width: 64px;
height: 38.12px;
cursor: pointer;
outline: none;
border: none;
box-shadow: none;
margin-left: -1px;
}
</style>
<div>
<input id="ba-slider" class="ba-slider" type="range" min="0" max="100" step="1" value="50">
</div>
</div>
</form>Name: wf-form-Before-After-Slider — GET
<form id="wf-form-Before-After-Slider" name="wf-form-Before-After-Slider" data-name="Before After Slider" method="get" data-wf-page-id="64b85a416741fe7c912424a9" data-wf-element-id="8251b795-560c-bf7a-9719-5444a5e025ca"
aria-label="Before After Slider">
<div ba-slider-id="Tajah" class="html-embed-2 w-embed">
<style>
input[type="range"] {
-webkit-appearance: none;
/* Hides the slider so that custom slider can be made */
width: 100%;
/* Specific width is required for Firefox. */
background: transparent;
/* Otherwise white in Chrome */
}
input[type="range"]:focus {
outline: 1px solid rgba(0, 0, 0, 0);
/* Removes the blue border. You should probably do some kind of focus styling for accessibility reasons though. */
}
input[type="range"]::-ms-track {
width: 100%;
cursor: pointer;
/* Hides the slider so custom styles can be added */
background: transparent;
border-color: transparent;
color: transparent;
}
/* Special styling for WebKit/Blink */
input[type="range"]::-webkit-slider-thumb {
-webkit-appearance: none;
background: no-repeat center/100% url("https://uploads-ssl.webflow.com/646e7e37a48980ea23027e0b/64a9bb1753a8cd97b6130dd6_slider-thumb.png");
width: 64px;
height: 38.12px;
cursor: pointer;
margin-top: -14px;
/* You need to specify a margin in Chrome, but in Firefox and IE it is automatic */
margin-left: -1px;
outline: none;
border: none;
box-shadow: none;
}
/* All the same stuff for Firefox */
input[type="range"]::-moz-range-thumb {
background: no-repeat center/100% url("https://uploads-ssl.webflow.com/646e7e37a48980ea23027e0b/64a9bb1753a8cd97b6130dd6_slider-thumb.png");
width: 64px;
height: 38.12px;
cursor: pointer;
outline: none;
border: none;
box-shadow: none;
margin-left: -1px;
}
</style>
<div>
<input id="ba-slider" class="ba-slider" type="range" min="0" max="100" step="1" value="50">
</div>
</div>
</form>Text Content
$40 OFF YOUR JEUVEAU® TREATMENT! Vitality Health and Wellness — Waycross, GA 31501 912-785-3679 contact us BOOK A FREE CONSULTATION Get your free consultation and check out the video to learn more! Submit By submitting this form, I consent to Evolus, Inc., under its express authorized partnership with Vitality Health and Wellness, to use my information for contact regarding consultations or services. I understand that Evolus, Inc. manages this process on behalf of Vitality Health and Wellness. This may include automated messages. As outlined in the Privacy Policy I am aware I can opt out of these communications at any time. VITALITY HEALTH AND WELLNESS LOCATION 700 Riverside Ave, Waycross, GA 31501 PHONE 912-785-3679 × CHECK OUT REAL RESULTS Day 0 Day 2 Day 30 Day 120 Day 0 Day 2 Day 30 Day 120 Soo Youn Soo Youn Soo Youn Soo Youn David David David David Arielle Arielle Arielle Arielle Sarah Sarah Sarah Sarah Tajah Tajah Tajah Tajah Soo Youn David Arielle Sarah Tajah At maximum frown. Jeuveau® patient. Individual results may vary. In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful. In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3 In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful. In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful. In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3 In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful. In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful. In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3 In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful. In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful. In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3 In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful. In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful. In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3 In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful. Soo Youn David Arielle Sarah Tajah At maximum frown. Jeuveau® patient. Individual results may vary. In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful. In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3 In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful. In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful. In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3 In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful. In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful. In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3 In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful. In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful. In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3 In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful. In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful. In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3 In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful. 2 DAYS How soon you could start to see results* 4 MONTHS How long your results could last** *About 50% of patients begin showing improvement after two days (≥1-grade improvement by physician assessment).2 Most patients (~69%) achieve complete results by day 30 (≥2-grade improvement by physician and patient assessments).3 **On average, Jeuveau patients receive 3 treatments a year.1 VITALITY HEALTH AND WELLNESS Meet Mandy McCook Smith, PA-C * FAQS WHAT IS JEUVEAU AND HOW DOES JEUVEAU WORK? You know those pesky lines between your eyebrows that won’t go away? They're called glabellar lines, also referred to as "frown lines" or "11s." Jeuveau is a prescription injectable neurotoxin treatment that works to temporarily improve the appearance of moderate to severe frown lines in adults by preventing your nerves from telling your facial muscles to contract. When expertly injected by a professional like our trained staff, Jeuveau achieves a smooth, natural-looking result without that frozen look. IS JEUVEAU TREATMENT PAINFUL? Jeuveau is injected using tiny needles. Most people report feeling little more than a minor pinch during treatment. If you’re concerned about pain during your appointment, ask your injector about ways to make your treatment more comfortable. A typical Jeuveau treatment only takes ten minutes. HOW SOON WILL I SEE JEUVEAU RESULTS? About 50% of patients begin showing improvement after two days (≥1-grade improvement by physician assessment). Most patients (~69%) achieve complete results by day 30 (≥2-grade improvement by physician and patient assessments). On average, Jeuveau patients receive 3 treatments a year. IS THERE ANY DOWN TIME AFTER JEUVEAU? Generally, there is no recovery period associated with a Jeuveau procedure, so you may get right back to your day after treatment, with minor activity modifications. Your injector may advise you to avoid lying down for 4 hours after treatment and avoid exercise for 24 hours following treatment. Having said that, some people may experience mild swelling or bruising at the injection site for a few days. Don’t book your treatment within days of a big occasion as you want enough time for your results to kick in. WILL MY JEUVEAU RESULTS LOOK NATURAL? Many patients hesitate to try a neuromodulator like Jeuveau because of the widespread notion that they may look “frozen” or unlike themselves after treatment. When working with a trusted and trained professional, you’re in capable hands. Your health, safety and desired results are our top priority. We’re here to help you look and feel your best. BYE, FROWN LINES. HELLO JEUVEAU®! Request an Appointment Jeuveau® is a prescription medicine that is injected into muscles and used in adults for a short period of time (temporary) to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines). 1. Jeuveau (package insert). Newport Beach, CA :Evolus, Inc. 2020 2. Rzany B. A multicenter, randomized, double-blind, placebo-controlled, single-dose, phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients. Aesthet Surg J. 2020;40(4):413-429. 3. Beer K. Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from identical phase III studies. Dermatol Surg. 2019;45(11):1381-1393 VITALITY HEALTH AND WELLNESS, WAYCROSS, GA Official provider of Jeuveau by Evolus Address 700 Riverside Ave, Waycross, GA 31501 Hours Monday: 8 AM - 5 PM Tuesday: 8 AM - 5 PM Wednesday: 8 AM - 5 PM Thursday: 8 AM - 6 PM Friday: 8 AM - 5 PM Saturday and Sunday: Closed. Phone 912-785-3679 Site Ownership and Partnership Disclaimer This site is owned and operated by Evolus, Inc., 520 Newport Center Drive, Suite 1200, Newport Beach, CA 92660. The content, services, and promotions on this site are provided in collaboration with the named practice, Vitality Health and Wellness, with whom Evolus, Inc. has an express authorized co-branded marketing partnership. Vitality Health and Wellness is an official provider of Jeuveau by Evolus, and has entrusted us with express permission to handle appointment scheduling, digital interactions and information dissemination on its behalf. All aspects of this page — including the consultation form and the provisioned contact number 912-785-3679 — are managed by Evolus, Inc. as part of our authorized service offering to facilitate direct and efficient interaction with Vitality Health and Wellness. All information submitted through this site is intended for use by Evolus, Inc. and Vitality Health and Wellness for the purpose of providing consultation and appointment scheduling services. We do not sell or share this information with third parties outside of this partnership. This site is intended for US residents only. Terms & ConditionsPrivacy Policy ©2024 Evolus, Inc. All rights reserved. All trademarks are the property of their respective owners. Expand + IMPORTANT SAFETY INFORMATION FOR JEUVEAU® (PRABOTULINUMTOXINA-XVFS) JEUVEAU® may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of JEUVEAU®: * Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months. * Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, trouble swallowing. IMPORTANT SAFETY INFORMATION FOR JEUVEAU® (prabotulinumtoxinA-xvfs) JEUVEAU® may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of JEUVEAU®: * Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months. * Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, trouble swallowing. Do not use JEUVEAU® if you: are allergic to any of the ingredients in JEUVEAU® (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as rimabotulinumtoxinB (MYOBLOC®), onabotulinumtoxinA (BOTOX®/BOTOX® Cosmetic), abobotulinumtoxinA (DYSPORT®), or incobotulinumtoxinA (XEOMIN®); have a skin infection at the planned injection site; or are a child. JEUVEAU dosing units are not the same as, or comparable to, any other botulinum toxin product. Tell your healthcare provider about all your muscle or nerve conditions, such as ALS or Lou Gehrig’s disease, Myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including difficulty swallowing and difficulty breathing from typical doses of JEUVEAU®. Tell your healthcare provider about all your medical conditions, including: any side effects from botulinum toxin products, including dry eye; breathing, swallowing, bleeding, or heart problems; plans to have surgery; weakness of forehead muscles; drooping eyelids; have had surgery on your face; are pregnant or breastfeeding or plan to become pregnant or breastfeed (it is not known if JEUVEAU® can harm your unborn baby or passes into breast milk). Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using JEUVEAU® with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your healthcare provider that you have received JEUVEAU® in the past. Especially tell your healthcare provider if you: have received any other botulinum toxin product in the past and the last 4 months, and exactly which product you received (such as BOTOX, BOTOX Cosmetic, MYOBLOC, DYSPORT, or XEOMIN). JEUVEAU® may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of treatment with JEUVEAU®. If this happens, do not drive a car, operate machinery, or do other dangerous activities. JEUVEAU® can cause other serious side effects including: Allergic reactions such as itching, rash, red itchy welts, wheezing, trouble breathing, asthma symptoms, or dizziness or feeling faint. Tell your healthcare provider or get emergency medical help right away if you develop wheezing or trouble breathing, or if you feel dizzy or faint. Heart problems. Irregular heartbeat and heart attack that have caused death, have happened in some people who received botulinum toxin products. Eye problems such as dry eye, reduced blinking, and corneal problems. Tell your healthcare provider if you develop eye pain or irritation, sensitivity to light, or changes in your vision. The most common side effects include: headache; eyelid drooping, upper respiratory tract infection, and increased white blood cell count. APPROVED USE JEUVEAU® is a prescription medicine that is injected into muscles and used in adults for a short period of time (temporary) to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines). The risk information provided here is not complete. For more information about JEUVEAU, see the full Prescribing Information including BOXED WARNING, and Medication Guide, or talk to your healthcare provider. To report side effects associated with use of JEUVEAU, please call 1-877-EVOLUS1/1-877-386-5871. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. Exclusively licensed and manufactured for: Evolus, Inc., 520 Newport Center Drive, Suite 1200, Newport Beach, CA 92660 ©2024 Evolus, Inc. All rights reserved. All trademarks are the property of their respective owners *Your Club Evolus membership covers 20 units of Jeuveau per treatment, with a minimum of 90 days between each treatment. Units do not accrue if you wait more than 90 days between treatments. You will pay your provider directly for any additional treatments you receive. Cannot be combined with any other offer. Club Evolus members will be automatically opted out of Evolus Rewards™ upon enrollment. You can manage your Club Evolus account and payment method through your club.evolus.com login. If you cancel within the first three months a $100 cancellation fee will apply. Your Club Evolus membership is non-transferable and payments are non-refundable. US-JUV-2300386v2